Name | Title | Contact Details |
---|---|---|
Tony Deigh |
Executive Vice President of Data Science and Analytics Engineering and Chief Data Officer | Profile |
Paw Andersen |
Chief Technology Officer | Profile |
Kevin Rickard |
Vice President Information Technology and | Profile |
Netwin solution is a Westminster, CA-based company in the Software and Internet sector.
Telarix, named the market leader in Interconnect Business Optimization solutions, helps solve a new set of challenges for international service providers with its software, iXTools® and iXLink®. The products, offered in both a licensed and SaaS version, are able to support voice, video, data and SMS. iXLink® enables carriers, resellers and emerging market providers to automate their wholesale interconnect purchase processes. With over 3,300 members exchanging over 50,000 documents monthly in a secure and collaborative business environment, iXLink® has proven to be the solution to have. Its product set includes Price List Receipt, Price List Distribution, Bill Receipt and Bill Distribution. Newly enhanced premium features include dial code analysis and discrepancy management, line by line invoice reconciliation and audit and listed least cost routing report, all designed to focus on improving the bottom line.
Desert Mirage Marketing is a Mesa, AZ-based company in the Software and Internet sector.
HyperTech Designs is a Adrian, MI-based company in the Software and Internet sector.
Immunome is a biotechnology company with a growing pipeline of cancer immunotherapies fueled by the human immune system. Our unique and powerful immunotherapy discovery engine leverages “most highly educated” immune systems from patients who have already learned how to fight off their disease. This proprietary technology platform enables the simultaneous discovery of novel antigens and the patient-derived, native antibodies that target those antigens. We then employ a battery of high-content screening technologies to identify specific and high-affinity antibodies that offer significant therapeutic potential to change the way we treat cancer.